Together, our findings suggest that targeting MYC indirectly by inhibiting the HSP90 machinery, using 17-DMAG as a potential chemotherapeutic drug, may be an alternative therapeutic strategy for Burkitt lymphoma and possibly other MYC-associated cancers. The gene discussed is MYC; the disease is cancer.